Medipal Holdings (7459) AI Stock Analysis

• Market Cap: ¥493.15B
• Dividend Yield: 2.52%
• Average Volume (3M): 365.88K
• Price to Earnings (P/E): 13.6
• Beta (1Y): 0.46
• Revenue Growth: 3.88%
• EPS Growth: -10.72%
• Country: JP
• Employees: 13,075
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Distribution
• EPS (TTM): 60.63
• Shares Outstanding: 219,226,040
• 10 Day Avg. Volume: 365,940
• 30 Day Avg. Volume: 365,883
• PEG Ratio: -8.97
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 0.13
• P/FCF Ratio: 9.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 186.58
• Revenue Forecast (FY): ¥3.78T

• Rating: 68 Neutral
• Price Target: ¥2,720.00 ▲(5.92% Upside)

Medipal Holdings' overall stock score is driven by its solid financial performance and reasonable valuation. The technical analysis indicates a bearish trend, which slightly offsets the positive financial outlook. The lack of earnings call data and corporate events does not impact the score.

Medipal Holdings Business Overview & Revenue Model

Company Description

Medipal Holdings (7459) is a leading Japanese company operating in the healthcare and medical supplies sector. The company primarily focuses on the manufacture and distribution of medical products, including pharmaceuticals, medical devices, and healthcare-related services. Medipal Holdings serves a diverse range of customers, including hospitals, clinics, and pharmacies, and is committed to improving healthcare outcomes through innovative solutions and high-quality products.

How the Company Makes Money

Medipal Holdings generates revenue through several key streams, primarily from the sale of medical supplies and pharmaceuticals to healthcare institutions. The company's revenue model is supported by a strong distribution network, which allows it to reach a wide array of clients in the healthcare sector. Additionally, Medipal Holdings benefits from partnerships with various manufacturers and suppliers, ensuring access to a broad portfolio of products. The company also engages in value-added services such as logistics and inventory management for its clients, further contributing to its earnings. By focusing on both product sales and service offerings, Medipal Holdings maintains a diversified revenue base that helps mitigate market risks.

Medipal Holdings Financial Statement Overview

Summary

Medipal Holdings shows strong revenue growth and a robust balance sheet with minimal leverage. However, there is room for improvement in operational efficiency and cash flow stability.

Income Statement

Medipal Holdings has shown a strong revenue growth rate of 5.57% in the latest year, indicating a positive trajectory. The gross profit margin is stable at around 6.6%, and the net profit margin is consistent at approximately 1.1%. However, the EBIT and EBITDA margins are relatively low, suggesting room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet is robust, with a very low debt-to-equity ratio of 0.0067, indicating minimal leverage and financial risk. The return on equity is healthy at 6.5%, reflecting effective use of shareholder funds. The equity ratio is strong, suggesting a solid capital structure.

Cash Flow

Medipal Holdings has demonstrated strong free cash flow growth, although the operating cash flow to net income ratio is modest at 0.06. The free cash flow to net income ratio is high at 0.85, indicating good cash generation relative to net income. However, the volatility in free cash flow growth rates suggests potential fluctuations in cash flow stability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.71T	3.67T	3.56T	3.36T	3.29T	3.21T
Gross Profit	254.44B	242.25B	246.66B	224.31B	217.44B	214.26B
EBITDA	90.71B	95.16B	92.73B	84.74B	71.64B	64.08B
Net Income	40.86B	40.28B	41.47B	38.81B	29.42B	23.93B
Balance Sheet
Total Assets	1.85T	1.82T	1.80T	1.70T	1.71T	1.68T
Cash, Cash Equivalents and Short-Term Investments	246.03B	261.41B	230.47B	195.03B	261.92B	241.52B
Total Debt	38.85B	4.17B	1.46B	7.38B	30.08B	30.58B
Total Liabilities	1.09T	1.07T	1.06T	1.02T	1.06T	1.04T
Stockholders Equity	616.58B	619.57B	600.35B	561.36B	530.30B	523.01B
Cash Flow
Free Cash Flow	0.00	51.70B	42.45B	2.64B	42.34B	18.78B
Operating Cash Flow	0.00	60.56B	61.84B	16.15B	61.22B	34.45B
Investing Cash Flow	0.00	-3.36B	-7.82B	-39.49B	-24.34B	-2.94B
Financing Cash Flow	0.00	-25.95B	-25.25B	-43.54B	-16.47B	-16.00B

Medipal Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2568.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7459, the sentiment is Positive. The current price of 2568 is below the 20-day moving average (MA) of 2581.25, below the 50-day MA of 2576.72, and above the 200-day MA of 2401.35, indicating a bullish trend. The MACD of 19.22 indicates Negative momentum. The RSI at 61.58 is Neutral, neither overbought nor oversold. The STOCH value of 61.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:7459.

Medipal Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2784	74 Outperform	$415.53B	14.44	4.94%	3.03%	5.11%	-20.51%
9987	69 Neutral	$327.42B	13.10	7.09%	1.68%	1.37%	-1.55%
7459	68 Neutral	¥493.15B	13.62	6.39%	2.52%	3.88%	-10.72%
3151	67 Neutral	¥57.86B	6.30	―	4.61%	2.23%	72.07%
3349	60 Neutral	¥555.13B	17.83	―	0.92%	3.73%	18.84%
8129	60 Neutral	¥303.75B	14.23	―	1.76%	2.31%	19.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Medipal Holdings Corporate Events

Medipal Holdings Advances Treasury Stock Acquisition

Medipal Holdings Corporation announced the progress of its treasury stock acquisition, having purchased 400,000 shares for approximately JPY 1.07 billion between September 1 and September 30, 2025. This move is part of a larger plan resolved in May 2025 to acquire up to 4 million shares, aiming to strengthen shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2740.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.

Medipal Holdings Advances Treasury Stock Acquisition Strategy

Medipal Holdings Corporation, a company listed on the Tokyo Stock Exchange, has been actively acquiring its own treasury stock as part of a strategic financial maneuver approved by its Board of Directors. Between August 1 and August 31, 2025, the company acquired 523,100 shares of common stock for approximately JPY 1.37 billion through market purchases. This acquisition is part of a larger plan to buy back up to 4 million shares by October 31, 2025, with a total budget of 8 billion yen. As of the end of August, Medipal has acquired 2,211,000 shares, amounting to over JPY 5.3 billion, indicating significant progress in its stock repurchase strategy.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2740.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.

Medipal Holdings Sees Q1 Sales Growth Amid Strategic Changes

Medipal Holdings reported a 3.9% increase in net sales to ¥945,159 million for the first quarter ending June 30, 2025, compared to the same period last year. Operating profit rose by 5.8%, and ordinary profit increased by 7.8%. Despite these gains, comprehensive income decreased by 35.1%. The company plans to maintain its dividend payments and has announced a share buyback for the fiscal year ending March 31, 2026. The removal of MVC CO., LTD. from the scope of consolidation was noted as it was absorbed by a wholly-owned subsidiary.

The most recent analyst rating on (JP:7459) stock is a Hold with a Yen2510.00 price target. To see the full list of analyst forecasts on Medipal Holdings stock, see the JP:7459 Stock Forecast page.